Sherry Sherman

Preface

Ann NY Acad Sci 2001 949: xi. [Full Text] [PDF]  

Part I. Basic Biology of SERMs:

RONALD MARGOLIS

The Basic Biology of SERMs: Introduction

Ann NY Acad Sci 2001 949: 1-2. [Full Text] [PDF]  

NEIL J. McKENNA and BERT W. O'MALLEY

Nuclear Receptors, Coregulators, Ligands, and Selective Receptor Modulators: Making Sense of the Patchwork Quilt

Ann NY Acad Sci 2001 949: 3-5. [Abstract] [Full Text] [PDF]  

BENITA S. KATZENELLENBOGEN, JUN SUN, WILLIAM R. HARRINGTON, DENNIS M. KRAICHELY, DESHANIE GANESSUNKER, and JOHN A. KATZENELLENBOGEN

Structure-Function Relationships in Estrogen Receptors and the Characterization of Novel Selective Estrogen Receptor Modulators with Unique Pharmacological Profiles

Ann NY Acad Sci 2001 949: 6-15. [Abstract] [Full Text] [PDF]  

DONALD P. McDONNELL, CHING-YI CHANG, and JOHN D. NORRIS

Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the Quest for the Perfect SERM

Ann NY Acad Sci 2001 949: 16-35. [Abstract] [Full Text] [PDF]  

JUDITH M. A. EMMEN and KENNETH S. KORACH

Developing Animal Models for Analyzing SERM Activity

Ann NY Acad Sci 2001 949: 36-43. [Abstract] [Full Text] [PDF]  

ARUN K. ROY, RAKESH K. TYAGI, CHUNG S. SONG, YAN LAVROVSKY, SOON C. AHN, TAE-SUNG OH, and BANDANA CHATTERJEE

Androgen Receptor: Structural Domains and Functional Dynamics after Ligand-Receptor Interaction

Ann NY Acad Sci 2001 949: 44-57. [Abstract] [Full Text] [PDF]  

EVAN R. SIMPSON, COLIN CLYNE, CAROLINE SPEED, GARY RUBIN, and SERDAR BULUN

Tissue-Specific Estrogen Biosynthesis and Metabolism

Ann NY Acad Sci 2001 949: 58-67. [Abstract] [Full Text] [PDF]  

Part II. Cancer Treatment and Prevention:

BARBARA K. DUNN and BARRY KRAMER

Cancer Treatment and Prevention: Introduction

Ann NY Acad Sci 2001 949: 68-71. [Full Text] [PDF]  

V. CRAIG JORDAN

The Past, Present, and Future of Selective Estrogen Receptor Modulation

Ann NY Acad Sci 2001 949: 72-79. [Abstract] [Full Text] [PDF]  

ANTONIO C. WOLFF and NANCY E. DAVIDSON

Use of SERMs for the Adjuvant Therapy of Early-Stage Breast Cancer

Ann NY Acad Sci 2001 949: 80-88. [Abstract] [Full Text] [PDF]  

KATHLEEN I. PRITCHARD

Breast Cancer Prevention with Selective Estrogen Receptor Modulators: A Perspective

Ann NY Acad Sci 2001 949: 89-98. [Abstract] [Full Text] [PDF]  

NORMAN WOLMARK and BARBARA K. DUNN

The Role of Tamoxifen in Breast Cancer Prevention: Issues Sparked by the NSABP Breast Cancer Prevention Trial (P-1)

Ann NY Acad Sci 2001 949: 99-108. [Abstract] [Full Text] [PDF]  

TREVOR J. POWLES

The Royal Marsden Hospital (RMH) Trial: Key Points and Remaining Questions

Ann NY Acad Sci 2001 949: 109-112. [Abstract] [Full Text] [PDF]  

ALIANA GUERRIERI-GONZAGA, ARIANNA GALLI, NICOLE ROTMENSZ, and ANDREA DECENSI

The Italian Breast Cancer Prevention Trial with Tamoxifen: Findings and New Perspectives

Ann NY Acad Sci 2001 949: 113-122. [Abstract] [Full Text] [PDF]  

J. CUZICK

A Brief Review of the International Breast Cancer Intervention Study (IBIS), the Other Current Breast Cancer Prevention Trials, and Proposals for Future Trials

Ann NY Acad Sci 2001 949: 123-133. [Abstract] [Full Text] [PDF]  

MAURA N. DICKLER and LARRY NORTON

The MORE Trial: Multiple Outcomes for Raloxifene Evaluation: Breast Cancer as a Secondary End Point: Implications for Prevention

Ann NY Acad Sci 2001 949: 134-142. [Abstract] [Full Text] [PDF]  

RICHARD DAY

Quality of Life and Tamoxifen in a Breast Cancer Prevention Trial: A Summary of Findings from the NSABP P-1 Study

Ann NY Acad Sci 2001 949: 143-150. [Abstract] [Full Text] [PDF]  

Part III. Cardiovascular Disease:

DAVID J. GORDON

Selective Estrogen Receptor Modulators and Cardiovascular Disease: Introduction

Ann NY Acad Sci 2001 949: 151-152. [Full Text] [PDF]  

DAVID M. HERRINGTON and KAREN POTVIN KLEIN

Cardiovascular Trials of Estrogen Replacement Therapy

Ann NY Acad Sci 2001 949: 153-162. [Abstract] [Full Text] [PDF]  

BRIAN W. WALSH

The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors

Ann NY Acad Sci 2001 949: 163-167. [Abstract] [Full Text] [PDF]  

ARNON BLUM and RICHARD O. CANNON, III

Selective Estrogen Receptor Modulator Effects on Serum Lipoproteins and Vascular Function in Postmenopausal Women and in Hypercholesterolemic Men

Ann NY Acad Sci 2001 949: 168-174. [Abstract] [Full Text] [PDF]  

MARY CUSHMAN

Effects of Estrogen and Selective Estrogen Receptor Modulators on Hemostasis and Inflammation: Potential Differences among Drugs

Ann NY Acad Sci 2001 949: 175-180. [Abstract] [Full Text] [PDF]  

LORI MOSCA

Rationale and Overview of the Raloxifene Use for the Heart (RUTH) Trial

Ann NY Acad Sci 2001 949: 181-185. [Abstract] [Full Text] [PDF]  

Part IV. Osteoporosis:

SARALYN MARK and JHUMKA GUPTA

Prevention and Treatment of Osteoporosis: Introduction

Ann NY Acad Sci 2001 949: 186-187. [Full Text] [PDF]  

SHERRY SHERMAN

Preventing and Treating Osteoporosis: Strategies at the Millennium

Ann NY Acad Sci 2001 949: 188-197. [Abstract] [Full Text] [PDF]  

STEVEN R. CUMMINGS

The Paradox of Small Changes in Bone Density and Reductions in Risk of Fracture with Raloxifene

Ann NY Acad Sci 2001 949: 198-201. [Full Text] [PDF]  

Part IV. Cognitive Function:

ANDREW A. MONJAN

SERMs, Estrogen, and Cognitive Function: Introduction

Ann NY Acad Sci 2001 949: 202. [Full Text] [PDF]  

SUSAN M. RESNICK and PAULINE M. MAKI

Effects of Hormone Replacement Therapy on Cognitive and Brain Aging

Ann NY Acad Sci 2001 949: 203-214. [Abstract] [Full Text] [PDF]  

KRISTINE YAFFE

Estrogens, Selective Estrogen Receptor Modulators, and Dementia: What Is the Evidence?

Ann NY Acad Sci 2001 949: 215-222. [Abstract] [Full Text] [PDF]  

MARILYN M. MILLER, ANDREW A. MONJAN, and NEIL S. BUCKHOLTZ

Estrogen Replacement Therapy for the Potential Treatment or Prevention of Alzheimer's Disease

Ann NY Acad Sci 2001 949: 223-234. [Abstract] [Full Text] [PDF]  

Part V. Reproductive and Related Endocrine Considerations:

ESTELLA C. PARROTT

Reproductive and Related Endocrine Considerations: Introduction

Ann NY Acad Sci 2001 949: 235-236. [Full Text] [PDF]  

STEVEN R. GOLDSTEIN

The Effect of SERMs on the Endometrium

Ann NY Acad Sci 2001 949: 237-242. [Abstract] [Full Text] [PDF]  

SUSAN L. HENDRIX and S. GENE McNEELEY

Effect of Selective Estrogen Receptor Modulators on Reproductive Tissues Other Than Endometrium

Ann NY Acad Sci 2001 949: 243-250. [Abstract] [Full Text] [PDF]  

LEO PLOUFFE, JR. and SURESH SIDDHANTI

The Effect of Selective Estrogen Receptor Modulators on Parameters of the Hypothalamic-Pituitary-Gonadal Axis

Ann NY Acad Sci 2001 949: 251-258. [Abstract] [Full Text] [PDF]  

Part VI. Addressing the Benefit/Risk Ratio in Taking SERMs from Laboratory to Clinic:

FRANCIS L. BELLINO and LORETTA FINNEGAN

Translation of Basic Research: Finding the Perfect SERM: Introduction

Ann NY Acad Sci 2001 949: 259-260. [Full Text] [PDF]  

MARIETTA ANTHONY, J. KOUDY WILLIAMS, and BARBARA K. DUNN

What Would Be the Properties of an Ideal SERM?

Ann NY Acad Sci 2001 949: 261-278. [Abstract] [Full Text] [PDF]  

WORTA McCASKILL-STEVENS

Weighing the Benefits and Risks in Clinical Trials and Practice: Introduction

Ann NY Acad Sci 2001 949: 279. [Full Text] [PDF]  

JOSEPH P. COSTANTINO

Benefit/Risk Assessment of SERM Therapy: Clinical Trial versus Clinical Practice Settings

Ann NY Acad Sci 2001 949: 280-285. [Abstract] [Full Text] [PDF]  

MITCHELL H. GAIL

The Estimation and Use of Absolute Risk for Weighing the Risks and Benefits of Selective Estrogen Receptor Modulators for Preventing Breast Cancer

Ann NY Acad Sci 2001 949: 286-291. [Abstract] [Full Text] [PDF]  

ANNE L. TAYLOR

SERMs, Ethnicity, and Clinical Trials: Opportunities and Challenges

Ann NY Acad Sci 2001 949: 292-294. [Abstract] [Full Text] [PDF]  

ELIZABETH BARRETT-CONNOR

Raloxifene: Risks and Benefits

Ann NY Acad Sci 2001 949: 295-303. [Abstract] [Full Text] [PDF]  

SUSAN R. JOHNSON, BARBARA K. DUNN, and MARIETTA ANTHONY

Defining Benefits and Risks for SERMs in Clinical Trials and Clinical Practice

Ann NY Acad Sci 2001 949: 304-314. [Abstract] [Full Text] [PDF]  

Part VII. SERM Development in Industry, Academia, the NIH, and the FDA:

MARIETTA ANTHONY and KAREN JOHNSON

Roles of Industry, Government, and Academia in SERM Development: Introduction

Ann NY Acad Sci 2001 949: 315-316. [Full Text] [PDF]  

BARRY S. KOMM and C. RICHARD LYTTLE

Developing a SERM: Stringent Preclinical Selection Criteria Leading to an Acceptable Candidate (WAY-140424) for Clinical Evaluation

Ann NY Acad Sci 2001 949: 317-326. [Abstract] [Full Text] [PDF]  

JERRY P. LEWIS

The Breast Cancer Continuum: Insights from the Tamoxifen Trials Impact Future Drug Development Strategies

Ann NY Acad Sci 2001 949: 327-332. [Abstract] [Full Text] [PDF]  

SHERRY S. ANSHER and RAMI SCHARF

The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: Industry Collaborations in New Agent Development

Ann NY Acad Sci 2001 949: 333-340. [Abstract] [Full Text] [PDF]  

KEN KOBAYASHI and ROBERT J. DELAP

FDA Review Practices and Priorities for Drugs Used in Cancer Treatment

Ann NY Acad Sci 2001 949: 341-344. [Abstract] [Full Text] [PDF]  

SUSAN FLAMM HONIG

Tamoxifen for the Reduction in the Incidence of Breast Cancer in Women at High Risk for Breast Cancer

Ann NY Acad Sci 2001 949: 345-348. [Abstract] [Full Text] [PDF]  

NIKKI J. ZAPOL

Negotiating Industry-Sponsored Clinical Trial Agreements: A View from the Trenches

Ann NY Acad Sci 2001 949: 349-351. [Abstract] [Full Text] [PDF]  

BARBARA K. DUNN, MARIETTA ANTHONY, SHERRY SHERMAN, and JOSEPH P. COSTANTINO

Conclusions: Considerations Regarding SERMs

Ann NY Acad Sci 2001 949: 352-365. [Abstract] [Full Text] [PDF]  

SHERRY SHERMAN and BARBARA K. DUNN

Opportunities for Future Research

Ann NY Acad Sci 2001 949: 366-374. [Abstract] [Full Text] [PDF]  

Selective Estrogen Receptor Modulators (SERMs): Everything You Wanted to Know about SERMs:

Timeline of Key Events in SERM Development

Ann NY Acad Sci 2001 949: 377-380. [Full Text] [PDF]  

Estrogen Receptor-active Compounds, Estrogens and SERMs, of Historical and Current Interest

Ann NY Acad Sci 2001 949: 381. [Full Text]  

Model of Estrogen Receptor (ER) Action

Ann NY Acad Sci 2001 949: 382. [Full Text]  

Action of SERMs in Target Tissues

Ann NY Acad Sci 2001 949: 383. [Full Text]  

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.